Earlier this month, AMMF (The Alan Morement Memorial Fund), UK’s cholangiocarcinoma charity, organised the 2021 European Cholangiocarcinoma Conference. Cholangiocarcinoma (CCA), also known as bile duct cancer, is considered a rare digestive cancer affecting 6.000-8.000 people in Europe every year.

The Conference brought together clinicians, researchers and patients from all over the world. DiCE is pleased to share the key CCA patient challenges discussed at the event:

• Ensuring timely referrals to specialty centres
• The need for a long-term surveillance plan for survivors
• Research into biomarkers that will allow the development of personalised treatments
• The importance of molecular profiling; all patients should be offered molecular testing that could potentially provide them with access to targeted therapy or to clinical trials

Would you like to know more about CCA? Please see the related articles below or contact us:

• EMA Approves New Treatment Option for Certain Cholangiocarcinoma (CCA) Patients
• New Patient Leaflet Available for Patients with CCA and Gallbladder Cancers